Evidence map›Paper›PMID 32102476›Full record

ReviewCells2020

Nanoparticle-Based Delivery of Tumor Suppressor microRNA for Cancer Therapy.

Clodagh P O'Neill, Róisín M Dwyer

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy.International journal of molecular sciences · 2022
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Extracellular Vesicles: A New Star for Gene Drug Delivery.International journal of nanomedicine · 2024
    Review
  17. Article
  18. Review
  19. miRNA-Based Technologies in Cancer Therapy.Journal of personalized medicine · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Clodagh P O'NeillDiscipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, H91 YR71, Ireland.
Róisín M DwyerDiscipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, H91 YR71, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Improved understanding of microRNA expression and function in cancer has revealed a range of microRNAs that negatively regulate many oncogenic pathways, thus representing potent tumor suppressors. Therapeutic targeting of the expression of these microRNAs to the site of tumors and metastases provides a promising avenue for cancer therapy. To overcome challenges associated with microRNA degradation, transient expression and poor targeting, novel nanoparticles are being developed and employed to shield microRNAs for tumor-targeted delivery. This review focuses on studies describing a variety of both natural and synthetic nanoparticle delivery vehicles that have been engineered for tumor-targeted delivery of tumor suppressor microRNAs in vivo.

Indexed as

AnimalsAntineoplastic AgentsDendrimersExtracellular VesiclesGene Expression Regulation, NeoplasticHumansLiposomesMiceMicroRNAsMolecular Targeted TherapyNanoparticlesNeoplasmsPolyaminesXenograft Model Antitumor AssaysAntineoplastic AgentsDendrimersLipid NanoparticlesLiposomesMicroRNAsPoly(amidoamine)Polyaminescancer therapynanoparticle deliverytumor suppressor miRNA

Identifiers

PMID32102476
PMCPMC7072816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.